The role of liver transplant for intrahepatic cholangiocarcinoma: the UK NHSBT liver advisory group pilot programme

Abstract

Aim: Liver transplantation (LT) offers a potential curative treatment for non-metastatic intrahepatic cholangiocarcinoma (iCCA) in patients with chronic liver disease who are not amenable to liver resection (LR). Recent evidence suggests that cirrhotic patients with “very early” iCCA (single tumour, ≤ 2 cm) might benefit the most from LT, with a 5-year survival as high as 73%. In view of these developments, NHS Blood and Transplant’s Liver Advisory Group (LAG) established a Fixed Term Working Group (FTWG) to determine whether iCCA in patients with background cirrhosis should be considered for LT in the United Kingdom.

Methods: The FTWG included cholangiocarcinoma/LT patient representatives, experts in cholangiocarcinoma surgery/oncology, LT surgery, hepatology, hepatobiliary radiology, hepatobiliary pathology, nuclear medicine, and representation from various national hepatobiliary/oncology and transplant professional bodies. The objective was to make recommendations on appropriate indications, patient selection criteria, referral criteria, radiological assessment, transplant listing pathways, data management, and overall quality assurance.

Results: The FTWG recommended LT for very early iCCA in cirrhotics, who are otherwise not suitable for LR. In this paper, we summarise the selection criteria, patient pathways, referral framework, pre-transplant assessment criteria, outcome measures, and dissemination strategy for implementing this new indication for LT in the UK.

Conclusion: The introduction and evaluation of this pilot programme is an important breakthrough for iCCA patients in the UK, marking a significant stride in the field of transplant oncology. The results of this service evaluation will describe the role of LT in iCCA and guide future programmes to optimise patient selection, management, and outcomes.

Keywords

Intrahepatic cholangiocarcinoma / liver transplantation / working group / pilot programme / outcomes

References

[1] Wang J,Yang Y.Impact of cirrhosis on long-term survival outcomes of patients with intrahepatic cholangiocarcinoma.Cancer Med2022;11:3633-42 PMCID:PMC9554446

[2] Burton A,Driver RJ.HCC-UK/BASL/NCRAS Partnership Steering GroupPrimary liver cancer in the UK: incidence, incidence-based mortality, and survival by subtype, sex, and nation.JHEP Rep2021;3:100232 PMCID:PMC7966867

[3] Mazzaferro V,Roayaie S,Sapisochin G.Liver resection and transplantation for intrahepatic cholangiocarcinoma.J Hepatol2020;72:364-77

[4] Spolverato G,Ejaz A.Conditional probability of long-term survival after liver resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 535 patients.JAMA Surg2015;150:538-45

[5] Palmer WC.Are common factors involved in the pathogenesis of primary liver cancers? a meta-analysis of risk factors for intrahepatic cholangiocarcinoma.J Hepatol2012;57:69-76 PMCID:PMC3804834

[6] Thakral N,Nano O,Samuels S.Cirrhosis in intrahepatic cholangiocarcinoma: prognostic importance and impact on survival.BMC Gastroenterol2023;23:151 PMCID:PMC10183123

[7] Tamandl D,Gruenberger B,Klinger M.Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma.Ann Surg Oncol2008;15:2787-94

[8] de Jong MC,Sotiropoulos GC.Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.J Clin Oncol2011;29:3140-5

[9] Doussot A,Wiggers JK.Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: preoperative and postoperative prognostic models.J Am Coll Surg2016;223:493-505.e2 PMCID:PMC5003652

[10] Molina V,Sampson-Dávila J.Intention-to-treat curative liver resection in patients with "very early" intrahepatic cholangiocarcinoma.Langenbecks Arch Surg2020;405:967-75

[11] van Keulen AM,Erdmann JI.Major complications and mortality after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.Surgery2023;173:973-82

[12] Langella S,Ossola P.Recurrence after curative resection for intrahepatic cholangiocarcinoma: how to predict the chance of repeat hepatectomy?.J Clin Med2021;10:2820 PMCID:PMC8269164

[13] Tsilimigras DI,Moris D.A machine-based approach to preoperatively identify patients with the most and least benefit associated with resection for intrahepatic cholangiocarcinoma: an international multi-institutional analysis of 1146 patients.Ann Surg Oncol2020;27:1110-9

[14] O'Grady JG,Rolles K,Williams R.Liver transplantation for malignant disease. results in 93 consecutive patients.Ann Surg1988;207:373-9 PMCID:PMC1493443

[15] Pichlmayr R,Tusch G.Indications and role of liver transplantation for malignant tumors.Oncologist1997;2:164-70.

[16] Sapisochin G,Gastaca M."Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?.Am J Transplant2014;14:660-7

[17] Sapisochin G,Gastaca M.Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study.Ann Surg2014;259:944-52

[18] Sapisochin G,Rubbia-Brandt L.iCCA International ConsortiumLiver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment.Hepatology2016;64:1178-88

[19] De Martin E,Golse N.Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis.Liver Transpl2020;26:785-98

[20] Lunsford KE,Heyne K.Methodist-MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC)Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.Lancet Gastroenterol Hepatol2018;3:337-48

[21] McMillan RR,Kodali S.Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma.Am J Transplant2022;22:823-32

[22] Takahashi K,Burmeister CS.Intrahepatic cholangiocarcinoma in the liver explant after liver transplantation: histological differentiation and prognosis.Ann Transplant2016;21:208-15

[23] Ziogas IA,Economopoulos KP.Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates.Transplantation2021;105:2263-71

[24] Jung DH,Song GW.Clinicopathological features and prognosis of intrahepatic cholangiocarcinoma after liver transplantation and resection.Ann Transplant2017;22:42-52

[25] Safdar NZ,Faulkes R.Outcomes after liver transplantation with incidental cholangiocarcinoma.Transpl Int2022;35:10802 PMCID:PMC9667791

[26] Rayar M,Houssel-Debry P,Sulpice L.Multimodal Therapy including Yttrium-90 radioembolization as a bridging therapy to liver transplantation for a huge and locally advanced intrahepatic cholangiocarcinoma.J Gastrointestin Liver Dis2016;25:401-4

[27] Sapisochin G,Lerut J.Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS transplant oncology consensus conference.Transplantation2020;104:1125-30

[28] Akamatsu N,Hasegawa K.Liver transplantation for the solitary intrahepatic cholangiocarcinoma less than 2 cm in diameter.Hepatobiliary Surg Nutr2017;6:332-4 PMCID:PMC5673765

[29] Menon K,Murphy J.NHS Blood and Transplant Liver Transplantation for Colorectal Liver Metastases Fixed Term Working GroupLiver transplantation for isolated unresectable colorectal liver metastases - protocol for a service evaluation in the United Kingdom - UKCoMET study.HPB2023;25:684-92

[30] NHS blood and transplant. (POL195/14) - liver transplantation: selection criteria and recipient registration. Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/27372/pol195-120822.pdf [Last accessed on 2 Aug 2023]

[31] Liu Y,Mo X,He J.A deep learning workflow for mass-forming intrahepatic cholangiocarcinoma and hepatocellular carcinoma classification based on MRI.Curr Oncol2022;30:529-44 PMCID:PMC9857958

[32] Ni T,Wang WT,Zeng MS.Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.Br J Radiol2018;91:20180017 PMCID:PMC6209488

[33] Jeon Y,Rhee H.Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma.Hepatology2023;77:92-108

[34] Beetz O,Weigle CA.Proposal of a new definition of "very early" intrahepatic cholangiocarcinoma-a retrospective single-center analysis.J Clin Med2021;10:4073 PMCID:PMC8468271

[35] Pillai A.Mixed hepatocellular-cholangiocarcinoma: is it time to rethink consideration for liver transplantation?.Liver Transpl2018;24:1329-30

[36] Ma KW,She WH.Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? a propensity score-matched analysis.Hepatol Int2018;12:167-73

[37] Cannella R,Catania R.Magnetic resonance imaging of nonhepatocellular malignancies in chronic liver disease.Magn Reson Imaging Clin N Am2021;29:404-18

[38] Lee DD,Musto KR.Liver transplantation for intrahepatic cholangiocarcinoma.Liver Transpl2018;24:634-44

[39] Sapisochin G,Heimbach J.Liver transplantation for intrahepatic cholangiocarcinoma: ready for prime time?.Hepatology2022;75:455-72

[40] Moro A,Sahara K.The impact of preoperative CA19-9 and CEA on outcomes of patients with intrahepatic cholangiocarcinoma.Ann Surg Oncol2020;27:2888-901

[41] Wu H,Wang Z.Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma.Acta Radiol2023;64:926-35

[42] Min JH,Park HS.LI-RADS version 2018 targetoid appearances on gadoxetic acid-enhanced MRI: interobserver agreement and diagnostic performance for the differentiation of HCC and Non-HCC malignancy.AJR Am J Roentgenol2022;219:421-32

[43] Park S,Kim H.Subtype classification of intrahepatic cholangiocarcinoma using liver MR imaging features and its prognostic value.Liver Cancer2022;11:233-46 PMCID:PMC9218635

[44] Ma KW,Leung B.Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a meta-analysis.Medicine2019;98:e14013 PMCID:PMC6380775

[45] Bridgewater J,Palmer DH.BILCAP study groupLong-term outcomes and exploratory analyses of the randomized phase III BILCAP study.J Clin Oncol2022;40:2048-57

[46] Panayotova GG,Lunsford KE.Should we reevaluate liver transplantation as an alternative to resection for the treatment of intrahepatic cholangiocarcinoma?.Liver Transpl2020;26:748-50

[47] Gül-Klein S,Schöning W.The role of immunosuppression for recurrent cholangiocellular carcinoma after liver transplantation.Cancers2022;14:2890 PMCID:PMC9221145

[48] Patkowski W,Grąt M,Kornasiewicz O.Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.Transplant Proc2014;46:2774-6

[49] NCT02878473- Liver transplantation for early intrahepatic cholangiocarcinoma (LT for iCCA). Available from: https://clinicaltrials.gov/ct2/show/NCT02878473 [Last accessed on 2 Aug 2023]

[50] NCT04195503- Liver transplant for stable advanced intrahepatic cholangiocarcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT04195503 [Last accessed on 2 Aug 2023]

[51] NCT04556214- Liver transplantation for non-resectable intrahepatic cholangiocarcinoma: a prospective exploratory trial (TESLA Trial). Available from: https://clinicaltrials.gov/ct2/show/NCT04556214 [Last accessed on 2 Aug 2023]